Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/21/2017 12:31:30 PM - Followers: 41 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 4th quarter of 2017. A CML combination drug safety study for BP1001 is also expected to be completed by late 2017. Patent protection for their neutral lipid delivery system has been allowed.
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 6+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:!/4292/presentation/2610

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.

Zack's rating now equals hold.

Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3110   Go to 17:30 in the presentation. He says Brettj 09/21/17 12:31:30 PM
#3109   Brett, did someone say that BPTH started the Gpheart2016 09/21/17 12:00:45 PM
#3108   I believe if you go back and listen, Brettj 09/21/17 11:52:22 AM
#3107   Brettj, The term PN used was "days." He SJSTOCKSHARK 09/21/17 11:29:00 AM
#3106   So if BPTH really started phase 2 for Brettj 09/21/17 10:17:34 AM
#3105   Hi dmsrz8! I think the general consensus wordlender 09/20/17 12:11:01 PM
#3104   Any thoughts on the BP-1001 study here? I dmsrz8 09/20/17 09:42:26 AM
#3103   It somehow went by me that I had blairsoldman 09/18/17 09:49:38 PM
#3102   Moffat, Same here! SJSTOCKSHARK 09/18/17 08:09:29 PM
#3101   I have voted no the last couple years dmoffat 09/18/17 03:56:06 PM
#3100   BOld, All we can do to send a SJSTOCKSHARK 09/18/17 02:40:17 PM
#3099   Saying people are whining because they are unhappy dmoffat 09/18/17 12:28:01 PM
#3098   Whining takes many forms and the most prevalent blairsoldman 09/18/17 10:45:16 AM
#3097   SJ, the last part of your statement is dmoffat 09/16/17 08:59:41 PM
#3096   Snug, Did you listen to PN's talk? I SJSTOCKSHARK 09/16/17 06:51:56 PM
#3094   SJ, where did you see the confirmation that Snug9 09/16/17 02:25:20 AM
#3093   Pstates, the major change is the confirmation that SJSTOCKSHARK 09/15/17 06:35:43 PM
#3092   If we all start buying it will increase PStates 09/15/17 04:16:10 PM
#3091   SJ, I think the short interest has only Gpheart2016 09/15/17 04:04:33 PM
#3090   Allb, I do not expect a short covering. SJSTOCKSHARK 09/15/17 03:18:20 PM
#3089   Have a good weekend. Nice volume at the allbetson 09/15/17 02:55:42 PM
#3088   If you are right and I think you allbetson 09/15/17 02:55:42 PM
#3087   I put people who buy stocks in one TheDenny 09/15/17 02:37:19 PM
#3086   I hear you, we really shouldn't get too dmoffat 09/15/17 01:35:57 PM
#3085   I doubled my position today, was homing for ShadeTrader 09/15/17 01:34:48 PM
#3084   Whoopy ding. Only another $2.35 to go blairsoldman 09/15/17 11:56:35 AM
#3083   Lots of volume this morning, I hope good dmoffat 09/15/17 11:14:00 AM
#3082   Nice to dream. Just close up for today. allbetson 09/15/17 10:01:06 AM
#3081   Forget the ma. We can break 50 cents today. allbetson 09/15/17 07:55:37 AM
#3080   200 day moving average is .70 but we Gpheart2016 09/14/17 04:14:39 PM
#3079   Thank you SJSTOCKSHARK. I missed that response last The Carp 09/14/17 02:32:17 PM
#3078   Moffat, Both technical sites I follow have turned SJSTOCKSHARK 09/14/17 02:24:59 PM
#3077   CARP, Read post #3049 and consider the Brettj SJSTOCKSHARK 09/14/17 02:22:44 PM
#3076   $.70cents 200 day moving average. Go to: Barto 09/14/17 01:07:54 PM
#3075   I have tried to remain optimistic, and I The Carp 09/14/17 11:46:24 AM
#3074   Who knows what our resistance levels are if dmoffat 09/14/17 11:25:26 AM
#3073   I dream of big Pharma taking us out. dmoffat 09/14/17 11:18:19 AM
#3072   Snug, The comparison is a good one. Your SJSTOCKSHARK 09/14/17 10:43:22 AM
#3071   SJ, Puma was trading around $25 per share, Snug9 09/14/17 03:06:22 AM
#3070   Thank you SJS, For some reason I kept too simple 09/13/17 07:52:22 PM
#3069   Simple, Less people shorting means the market sentiment SJSTOCKSHARK 09/13/17 04:37:14 PM
#3068   Snug. PBYI is now over $100 per share SJSTOCKSHARK 09/13/17 04:26:57 PM
#3067   I have lost so much money in this Barto 09/13/17 04:10:29 PM
#3066   SJ, when you say short interest is down too simple 09/13/17 02:55:39 PM
#3065   Barto, it's a sad commentary that you are Snug9 09/13/17 12:05:11 PM
#3064   Short interest down 500k @ 2.44 million. We SJSTOCKSHARK 09/13/17 10:51:17 AM
#3063   Why would you sell now? I am down Barto 09/12/17 09:06:40 PM
#3062   ILuv, you have been accurate before but this SJSTOCKSHARK 09/12/17 08:27:25 PM
#3061   They will raise money before it gets too iloveu2 09/12/17 08:20:40 PM
#3060   Surprise, surprise, surprise! SJSTOCKSHARK 09/12/17 08:17:11 PM